GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Current Ratio

BRAIN Biotech AG (XTER:BNN) Current Ratio : 2.01 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BRAIN Biotech AG's current ratio for the quarter that ended in Mar. 2024 was 2.01.

BRAIN Biotech AG has a current ratio of 2.01. It generally indicates good short-term financial strength.

The historical rank and industry rank for BRAIN Biotech AG's Current Ratio or its related term are showing as below:

XTER:BNN' s Current Ratio Range Over the Past 10 Years
Min: 1.37   Med: 2.7   Max: 6.36
Current: 2.01

During the past 9 years, BRAIN Biotech AG's highest Current Ratio was 6.36. The lowest was 1.37. And the median was 2.70.

XTER:BNN's Current Ratio is ranked better than
51.5% of 1565 companies
in the Chemicals industry
Industry Median: 1.96 vs XTER:BNN: 2.01

BRAIN Biotech AG Current Ratio Historical Data

The historical data trend for BRAIN Biotech AG's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Current Ratio Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Current Ratio
Get a 7-Day Free Trial Premium Member Only 2.08 2.68 3.45 1.42 1.46

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.56 1.46 1.64 2.01

Competitive Comparison of BRAIN Biotech AG's Current Ratio

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Current Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Current Ratio distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Current Ratio falls into.



BRAIN Biotech AG Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

BRAIN Biotech AG's Current Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Current Ratio (A: Sep. 2023 )=Total Current Assets (A: Sep. 2023 )/Total Current Liabilities (A: Sep. 2023 )
=25.476/17.479
=1.46

BRAIN Biotech AG's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=29.303/14.576
=2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BRAIN Biotech AG  (XTER:BNN) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


BRAIN Biotech AG Current Ratio Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines